• Ian Milsom, Adrian Wagg, Matthias Oelke, and Christopher Chapple.
• Department of Obstetrics and Gynecology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
• Int. J. Clin. Pract. 2021 Apr 1; 75 (4): e13870e13870.

AimIn order to help physicians determine which drugs are the best for treating overactive bladder (OAB) symptoms, this review considered three questions: what are the patient's expectations? What information is generated by the Multicriteria Decision Analysis (MCDA) model? What can physicians expect from medical treatments?MethodsA comprehensive literature search was undertaken on these three topics in order to assist physicians regarding the optimum treatment modality for OAB.ResultsPatients' difficulties in reporting symptoms and their expectations of treatment outcomes interfere with the success of treatment. To assist physicians in meeting patients' expectations and to choose the most appropriate treatment, a new approach, recognised by the European Medicines Agency, the MCDA model was used to compare the benefits and safety of OAB treatments.ConclusionThe MCDA model is useful for comparing the benefit-safety profiles of OAB drugs in order to equip clinicians with information on the drug that might best meet their patient's needs. Flexibly dosed fesoterodine appeared to be most efficacious in resolving urgency and urgency incontinence compared with other drugs, and resolution of urinary urgency appears to be associated with a reduced number of reported adverse events.© 2020 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.

17 keywords...

hide…